NEU-723 / Neuron23 - LARVOL DELTA

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease. (PubMed, Bioorg Chem) - "Currently, five candidates, DNL201, DNL151, WXWH0226, NEU-723 and BIIB094, have advanced to clinical trials for PD treatment. In this review, we describe the structure, pathogenic mutations and the mechanism of LRRK2, and summarize the development of LRRK2 inhibitors in preclinical and clinical studies, trying to provide an insight into targeting LRRK2 for PD intervention in future."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • LRRK2

A Study to Assess NEU-723 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Terminated | Sponsor: Neuron23 Inc. | N=64 ➔ 40 | Trial completion date: Sep 2023 ➔ Jun 2023 | Active, not recruiting ➔ Terminated; Business decision

Enrollment change • Trial completion date • Trial termination

A Study to Assess NEU-723 in Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: Neuron23 Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed

PRECLINICAL DEVELOPMENT OF NEU-723, A LRRK2 INHIBITOR FOR THE TREATMENT OF PARKINSON'S DISEASE (ADPD 2023) - "NEU -723 is a potent and selective LRRK2 inhibitor both in vitro and in vivo. These properties, combined with favorable PK and preclinical safety profiles make it an excellent candidate for clinical development."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson's Disease (PRNewswire) - "Neuron23™ Inc...today announced that the Company recently initiated dosing in a Phase 1 clinical trial of NEU-723 for the treatment of Parkinson's disease. NEU-723 is a highly potent and selective brain-penetrant leucine-rich repeat kinase 2 (LRRK2) inhibitor. Variants in the LRRK2 gene are associated with Parkinson's disease and systemic inflammatory diseases....This first-in-human Phase 1 study...is a randomized, double-blind, placebo-controlled, single-ascending dose, multiple-ascending dose, single-site clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of NEU-723 in adult healthy volunteers."

Trial status • CNS Disorders • Parkinson's Disease

A Study to Assess NEU-723 in Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Neuron23 Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess NEU-723 in Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Neuron23 Inc.

New P1 trial

Participation in SoftBank Vision Fund 2, etc..LRRK2, TYK2 target pipeline development [Google translation] (Biospectator) - "Neuron 23 announced...that it had completed raising $100 million in Series C. The cumulative investment of Neuron23 so far is approximately $213.5 million....Neuron23 plans to use the investment to develop and operate a Parkinson's disease treatment and inflammatory disease pipeline that targets leucine-rich repeat kinase 2 (LRRK2) and tyrosine kinase 2 (TYK2). In particular, Neuron 23 plans to enter the Parkinson's disease clinical trial for the LRRK2 inhibitor 'NEU-723' within this year."

Financing • New trial • CNS Disorders • Parkinson's Disease